Hester Biosciences balance sheet

As of Mar 2026

Total assets: ₹678cr+3.8% on Mar 2025
Shareholders' equity: ₹368cr+12.6% on Mar 2025
Total debt: ₹188cr−9.4% on Mar 2025
Cash and investments: ₹2.8cr−50.5% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	411	233	239	259
	—	177	168	146
	0.4	0.6	0.6	0.5
	9.3	6.0	3.3	2.5
	40.3	34.1	29.9	0.0
	2.3	0.0	0.0	25.3
	2.3	5.6	3.8	4.6
	4.6	5.6	3.8	29.9
	3.7	2.6	2.5	4.5
	469	458	448	442
	72.5	70.4	75.6	84.8
	95.4	73.2	78.6	79.6
	2.8	5.6	12.7	13.2
	3.8	1.6	2.6	1.7
	0.1	5.8	5.9	6.0
	21.0	20.2	18.8	17.0
	123	106	119	117
	13.1	18.5	20.5	25.3
	209	195	215	228
	678	653	662	670
Equity
	8.5	8.5	8.5	8.5
	352	306	283	271
	360	314	292	280
	7.6	12.4	11.1	8.8
	368	327	303	289
Liabilities
	90.0	133	182	185
	7.3	6.3	8.3	6.3
	97.3	140	190	191
	2.3	2.8	2.5	1.9
	8.8	5.9	7.4	7.4
	3.1	3.2	3.7	32.2
	158	202	254	233
	98.3	74.4	57.3	83.3
	24.7	29.4	26.4	30.0
	14.2	10.4	12.8	16.8
	137	114	96.5	130
	1.5	1.0	0.8	0.5
	5.0	4.0	2.5	3.4
	5.2	6.0	6.1	14.7
	152	125	106	149
	310	327	359	381
	678	653	662	670
Liabilities — additional as-filed lines
	3.6	0.0	0.0	0.0
	46.1	50.0	50.0	0.0
Trade payables — MSME split
	6.4	2.5	—	—
	18.3	26.9	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HESTERBIO₹2,243.70

Hester Biosciences Limited

· Pharma & Health

₹ CrorePeersWINDLAS SYNCOMF NGLFINE INDOCO SAIPARENT JAGSNPHARM PANACEABIOMcap ₹1,909 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	258.9	239.5	232.7	411.1	411.1
+ Capital Work-in-Progress	146.1	168.1	176.7	—	—
+ Other Intangibles	0.5	0.6	0.6	0.4	0.4
+ Intangibles under Development	2.5	3.3	6.0	9.3	9.3
+ Investments (Equity Method)	0.0	29.9	34.1	40.3	40.3
+ Non-current Investments	25.3	0.0	0.0	2.3	2.3
+ Other Non-current Financial Assets	4.6	3.8	5.6	2.3	2.3
Non-current Financial Assets	29.9	3.8	5.6	4.6	4.6
+ Other Non-current Assets	4.5	2.5	2.6	3.7	3.7
Total Non-current Assets	442.4	447.7	458.2	469.4	469.4
Current Assets
+ Inventories	84.8	75.6	70.4	72.5	72.5
+ Trade Receivables	79.6	78.6	73.2	95.4	95.4
+ Cash & Cash Equivalents	13.2	12.7	5.6	2.8	2.8
+ Other Bank Balances	1.7	2.6	1.6	3.8	3.8
+ Short-term Loans	6.0	5.9	5.8	0.1	0.1
+ Other Current Financial Assets	17.0	18.8	20.2	21.0	21.0
Current Financial Assets	117.5	118.6	106.3	123.0	123.0
+ Other Current Assets	25.3	20.5	18.5	13.1	13.1
Total Current Assets	227.6	214.6	195.2	208.6	208.6
Total Assets	670.0	662.3	653.4	677.9	677.9
Equity
+ Equity Share Capital	8.5	8.5	8.5	8.5	8.5
+ Other Equity / Reserves	271.2	283.3	305.7	351.7	351.7
Equity — Owners of Parent	279.7	291.8	314.3	360.2	360.2
+ Minority Interest	8.8	11.1	12.4	7.6	7.6
Total Equity	288.5	302.9	326.7	367.8	367.8
Liabilities
+ Borrowings — Non-current	184.9	181.8	133.4	90.0	90.0
+ Other Non-current Financial Liab	6.3	8.3	6.3	7.3	7.3
Non-current Financial Liabilities	191.2	190.1	139.6	97.3	97.3
+ Provisions — Non-current	1.9	2.5	2.8	2.3	2.3
+ Deferred Tax Liabilities	7.4	7.4	5.9	8.8	8.8
+ Other Non-current Liabilities	32.2	3.7	3.2	3.1	3.1
Non-current Liabilities	232.7	253.7	201.5	157.7	157.7
+ Borrowings — Current	83.3	57.3	74.4	98.3	98.3
+ Trade Payables	30.0	26.4	29.4	24.7	24.7
+ Other Current Financial Liab	16.8	12.8	10.4	14.2	14.2
Current Financial Liabilities	130.1	96.5	114.2	137.2	137.2
+ Provisions — Current	0.5	0.8	1.0	1.5	1.5
+ Current Tax Liabilities	3.4	2.5	4.0	5.0	5.0
+ Other Current Liabilities	14.7	6.1	6.0	5.2	5.2
Current Liabilities	148.7	105.8	125.2	152.5	152.5
Total Liabilities	381.4	359.5	326.7	310.2	310.2
Total Equity & Liabilities	670.0	662.3	653.4	677.9	677.9
Liabilities — additional as-filed lines
+ Deferred Government Grants — Current	0.0	0.0	0.0	3.6	3.6
+ Deferred Government Grants — Non-current	0.0	50.0	50.0	46.1	46.1
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	2.5	6.4	6.4
+ Dues to Other Creditors — Current	—	—	26.9	18.3	18.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.